Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. It is very important to do your own analysis before making any investment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. It has real management. But realizing value in practice usually is a difficult endeavor. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Nasdaq Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Type a symbol or company name. This can prove to be a costly lesson to learn. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The second is that the balance sheet still needs some help. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Cost basis and return based on previous market day close. market." In November, Bharat Biotech began Phase 3 testing of Covaxin in India. It has real products. Investing is always a game of balancing risk and reward. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Objective investors could have clearly seen then that there actually were significant reasons to be concerned. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Plus500. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. Making the world smarter, happier, and richer. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. Do not expect a recovery in Ocugen stock. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. All rights reserved. But if they do, Ocugen stock at the least looks like an intriguing bet. That said, for investors who understand the potential downside, there is an intriguing story here. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Other than an emphasis on cell therapies, the companies had almost nothing in common. The potential synergies of such a union do not seem clear. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. Investors were hopeful that the small drugmaker would be able to win U.S. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. It's hard to say for sure. OCGN does not even appear to have an apparent reason to exist. ET on Friday. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. To be sure, current cash isnt enough. Investors were hopeful that the small drugmaker would be able to win U.S. Without NeoCart, that burn likely comes down. Ocugen isnt a promotional, fly-by-night penny stock. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Investors should worry about companies with no revenue even under the best of circumstances. What should investors do now? Type a symbol or company name. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." However, when that occurred, Ocugen stock lost most of its value. If you missed that action, you missed all the gains. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. The average Ocugen stock price for the last 52 weeks is 2.10. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Nasdaq In this case, shares rallied about four-fold in just a few days. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Honestly, OCGN stock is unlikely to survive. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. The FDA's decision not to issue EUA really wasn't all that surprising, though. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. All rights reserved. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. As of this writing, Matt did not hold a position in any of theaforementioned securities. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. 2023 InvestorPlace Media, LLC. Emergency Use . The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Its all about choice. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Like other life sciences companies involved in Covid-19 vaccine. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Sign up below to get this incredible offer! The company stated that it will pursue a path to file for full FDA approval of Covaxin. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. The Motley Fool has a disclosure policy. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. Copy and paste multiple symbols separated by spaces. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. However, sometimes the optimism isn't justified. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. 1125 N. Charles St, Baltimore, MD 21201. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. That's not going to happen now. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Investors who have owned stocks in the last year have generally experienced some big gains. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. At the beginning of 2020, Ocugen shares were trading at just 47 cents. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. Please check your download folder. The stock had gained some traction after they announced the Ocugen merger in April. Theres an opportunity here. If they invent a miracle treatment for a condition, the money will find its way to the stock. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. *Stock Advisor returns as of June 7, 2021. Accordingly, the analyst rates OCGN a Neutral (i.e. The Motley Fool has no position in any of the stocks mentioned. Most biotech companies have intriguing stories on paper; Ocugen is no different. Please check your download folder. I will concede this: The one great thing about the stock market is there is a style for everyone. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Written by While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. The content is intended to be used for informational purposes only. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. The chances of anything more are small but the rewards could be huge. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Theres even room for more lines. That's right -- they think these 10 stocks are even better buys. Click here to see what Matt has up his sleeve now. The Motley Fool has a disclosure policy. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Keith Speights has no position in any of the stocks mentioned. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. But there is no question some big-name stocks performed better than others along the way. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Theres even room for more lines. That doesnt mean success is guaranteed. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. The $25 million private placement executed before the merger brought in much-needed cash. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Maybe OCGN stock will be one of them again. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Keith Speights for The Ocugen deal is a way to salvage some limited value. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. The Motley Fool has a disclosure policy. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. That product drives the current bull case for Ocugen stock. The short answer is: everything. Unfortunately for longs, OCGN is much closer to the worst of conditions. How can we possibly evaluate a stock on a fundamental basis with that being reality? The company initiated its Phase 3 trial of OCU300 back in July 2018. Not an offer or recommendation by Stocktwits. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Our 3 Top Picks. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Can you feel the ground moving beneath your feet? When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. Type a symbol or company name. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. It means that institutional investors focused on the sector largely have passed on the pipeline. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Copyright 2023 InvestorPlace Media, LLC. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. At the time, Ocugen was left for dead. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. These options will be cheaper than owning the stock itself. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Ill be sticking to the stocks that are actually working. The Motley Fool->. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater.
Fairport Parade Route,
Tribunal Lay Member Vacancies,
Mercyone Waterloo Neurology,
Superfighters 5 Unblocked,
Articles O
ocugen stock crash 2018